25 results about "Keloid" patented technology

The invention discloses a genetic locus marker combination for diagnosis or prognosis evaluation of keloid susceptible population as well as a detection method and application of the genetic locus marker combination, and belongs to the field of detection, and genetic loci comprise the following loci: rs873549, rs1442440, rs2271289, rs17431184 and rs2299939. According to the invention, the genetic susceptibility of Keloid keloid in North China can be comprehensively predicted according to genotype detection results of the selected five gene loci. Therefore, targeted treatment on the patient is achieved, and the curing possibility of the patient is improved.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The invention relates to the technical field of keloid resection, and discloses a minimally invasive surgery device for keloid core resection, which comprises a body, and further comprises an outer sleeve fixedly connected to the front end of the body, the outer sleeve is of a slender hollow structure and is used for being inserted into keloid tissues through a skin tiny incision; the inner cutting tube is coaxially arranged in the outer sleeve and can rotate relative to the outer sleeve, and an annular cutting edge used for cutting keloid fibrous tissue is formed at the far end of the inner cutting tube; according to the minimally invasive surgery device for keloid core excision, the outer sleeve and the inner excision tube are coaxially arranged, and the annular cutting edge used for cutting keloid fibrous tissue is formed at the far end of the inner excision tube, so that the device can enter the keloid through a tiny incision of the skin; on the premise of reducing skin wounds, effective treatment of keloid core tissues is realized, and improvement of postoperative healing effect and appearance recovery are facilitated.

The disclosure relates to methods of treating and / or preventing scarring that would otherwise result from an incision to an area of skin. The methods comprise administering a composition comprising tropoelastin to an area of skin that is to receive an incision and / or after the incision. It is also contemplated that the compositions may reduce scar discoloration. Methods of preventing or reducing keloid re-occurrence are also provided.

The application of bazedoxifene as an active ingredient in the preparation of a drug for blocking the differentiation of fibroblasts of the IL-6 family / gp130 signal axis. It has been verified that in the microenvironment of skin tissue, the early or very early appearance of pro-fibrotic stimulating factors (such as IL-11 and / or IL-6) can significantly inhibit the initiation of the pro-fibrotic molecular program, avoid the abnormal activation of myofibroblasts, thereby inhibiting the differentiation of fibroblasts into myofibroblasts, and can effectively inhibit the fibroblast migration of skin fibroblasts induced by pro-fibrotic stimulating factors (especially IL-11), effectively prevent skin fibrosis, and thereby prevent the formation of keloid.

The invention relates to the field of biological medicines, and discloses application of a KIF20A expression inhibitor in preparation of a medicine for treating keloid. The KIF20A expression inhibitor is a substance capable of reducing mRNA (messenger ribonucleic acid) and / or protein level of KIF20A. The invention provides a novel medicine for treating keloid, the expression of targeted KIF20A can increase the apoptosis of keloid fibroblasts by causing keloid fibroblast G2 / M phase retardation, meanwhile, the migration ability of the keloid fibroblasts is reduced, and the medicine has a treatment effect on the keloid.

The invention discloses application of defacitinib in preparation of a medicine for treating keloid, and belongs to the technical field of biological medicine. Aiming at the problems that a traditional keloid treatment method is poor in curative effect, high in risk, high in cost and the like, the invention provides application of defacitinib in preparation of the medicine for treating keloid, the medicine can effectively inhibit keloid fibroblast proliferation and migration, and a safe and convenient treatment means with reliable curative effect is provided for keloid, so that the medicine has a good application prospect. The invention has important social significance and clinical application value.

The invention relates to the technical field of biological medicines, in particular to application of a small-molecule inhibitor MYF-03-176 in preparation of a medicine for treating and / or preventing keloid and the medicine. The MYF-03-176 can remarkably promote fibroblast apoptosis of keloid tissue and inhibit cell proliferation, the volume of the keloid tissue can be remarkably reduced by locally injecting the MYF-03-176 into an animal, the MYF-03-176 is expected to become an effective drug choice for treating the keloid, and the combined treatment effect of the MYF-03-176 and the A-type botulinum toxin is further improved.

The utility model belongs to the technical field of scar treatment devices, and relates to a medical silica gel particle application device for keloid external radiotherapy, which comprises a base layer, the base layer is a self-adhesive medical transparent silica gel sheet, one side of the base layer is an adhesive surface attached to the skin, and the other side of the base layer is a non-adhesive surface; the non-sticky surface forms a marking surface and is provided with a particle positioning mark corresponding to the scar; the colloid layer is arranged at the particle positioning mark and forms a lattice structure; the covering layer is a self-adhesive medical transparent silica gel sheet, one side of the covering layer is an adhesive surface attached to the base layer, and the other side of the covering layer is an outward non-adhesive surface; the base layer and the covering layer form a closed interlayer, and the colloid layer is closed in the interlayer and is isolated from the skin. The medical silica gel particle application device for the keloid external radiotherapy has the advantages of simple structure and convenience in operation, and is particularly suitable for being used in primary hospitals.

The application discloses application of a cytokine interleukin-17D (IL-17D) in preparation of a medicine for preventing and / or treating scars. IL-17D is highly expressed in fibroblasts, but is down-regulated in myofibroblasts in skin scars and keloids. Low expression of IL-17D makes IL-17D unable to inhibit expression of fibrosis-related genes, thus unable to inhibit differentiation of fibroblasts into myofibroblasts, thereby causing generation of scars. Overexpression of IL-17D or injection of recombinant IL-17D protein in a mouse full-thickness skin wound can significantly inhibit formation of scars; after IL-17D gene of the mouse is knocked out, expression of fibrosis-related genes in the skin wound is up-regulated, and scars after wound healing are obviously aggravated. Therefore, the application discloses that IL-17D can be used as a medicine for diagnosing and treating skin scars or keloids.

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic / injured area).

The invention relates to the technical field of keloid resection, and discloses a multi-bit minimally invasive surgery device for keloid trephine resection, which comprises a handle, and further comprises a rotating disc rotationally mounted at the front end of the handle; the cylinder grooves are annularly and uniformly formed in the rotating disc; a connecting cylinder is movably inserted into each cylinder groove, a ring drill bit is arranged at the first end of each connecting cylinder, and the second end of each connecting cylinder is detachably connected with the inner shaft; the inner shaft is movably and telescopically arranged in the handle and can freely rotate; according to the multi-drill-bit minimally invasive surgery device for keloid trephine resection, the rotating disc is arranged at the front end of the handle, and the multiple barrel grooves are annularly and evenly distributed in the rotating disc to integrate trephine bits with different diameters, so that an operator can rapidly select and switch the matched trephine bits in the same minimally invasive surgery process; therefore, the adaptive capacity of the device to keloids with different sizes and shapes is improved, and the replacement frequency of instruments in an operation is reduced.

The invention relates to the field of biological medicine, and discloses application of phytosphingosine in preparation of medicine for treating keloid. According to the present invention, the novel keloid treatment drug can be provided, and by injecting the phytosphingosine into the keloid, the keloid fibroblast G2 / M phase retardation can be caused, such that the apoptosis is increased, the keloid tissue weight is reduced, the fibrosis degree is reduced, and the treatment effect on the keloid is provided.

The invention relates to the technical field of biological medicines, in particular to application of a small-molecule inhibitor BAY-593 in preparation of a medicine for treating and / or preventing keloid. The BAY-593 can remarkably promote fibroblast apoptosis of keloid tissue and inhibit cell proliferation, the volume of the keloid tissue can be remarkably reduced by locally injecting the BAY-593 into animals in vivo, and the BAY-593 is expected to be an effective drug choice for treating keloid.

The utility model discloses a bent scalpel structure, which relates to the technical field of medical instruments and comprises a scalpel handle. The blade is detachably arranged on the knife handle, the appearance of the blade is in a bent arc shape, the cutting edge of the blade is arranged at the bent arc position, the blade is arranged to be in the bent arc shape and is slender than a common surgical knife, when keloid excision is carried out, the blade can carry out subcutaneous free excision, keloid tissue can be more flexibly excided, and the cutting efficiency is improved. And moreover, the damage to the epidermis is reduced, so that the operation of an operator is more flexible and convenient, and the operation speed can be increased to a certain extent.

The invention discloses a pharmaceutical composition for treating hypertrophic scars and / or keloids. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 15-25 parts of gallnut, 15-25 parts of smoked plum, 15-25 parts of senecio scandens, 15-25 parts of fructus cnidii, 10-20 parts of radix angelicae, 10-20 parts of cortex lycii radicis, 170-230 parts of vinegar and 170-230 parts of honey. The composition disclosed by the invention has the effects of detoxifying, diminishing swelling, astringing dampness and relieving itching. The traditional Chinese medicine composition has obvious effects on hypertrophic scars and keloids formed after trauma, operation, burns and scalds, acne, folliculitis and other inflammations, and itching and pain caused by the hypertrophic scars and keloids.

This application relates to the field of diagnostic reagents, specifically to a scar diagnostic reagent and its application. This application is the first to discover CD3+ in the peripheral blood of keloid patients. + CD8 + The study revealed a significant decrease in cytotoxic T cells, highlighting for the first time the crucial role of the immune microenvironment in the pathogenesis of keloids. Furthermore, it was the first time that sHLA-E expression was significantly different in normal individuals compared to patients with hypertrophic scars and keloids. Using sHLA-E as a diagnostic marker can differentiate between hypertrophic scars and keloids, which are traditionally considered pathological scars, and can also be used to assess the effectiveness of keloid treatment.

The invention relates to the technical field of medicine for resisting keloid. The invention discloses a pharmaceutical composition for resisting keloid, application and a preparation method. The pharmaceutical composition comprises a therapeutically effective amount of nicotinamide N-methyltransferase (NNMT) inhibitor and a pharmaceutically acceptable carrier. According to the invention, an NNMT inhibitor is taken as a core, and keloids are treated through metabolism-epigenetic regulation. NAD / SAM balance can be recovered, fibroblast activation, collagen deposition and chronic inflammation are inhibited from the source, and the anti-fibrosis and anti-inflammatory dual effects are achieved. The scheme adopts a local delivery system such as a microneedle and gel, has the advantages of strong targeting property, low toxicity, relapse prevention, clear mechanism and the like, and provides a root intervention strategy for skin fibrosis.

The application discloses a scar treatment gel material capable of reducing lactic acid generation, and belongs to the technical field of scar treatment. The material is prepared by the following steps: first, an intermediate A is obtained by esterification of 9-oxabicyclo[3.3.1]nonane-2,6-diol and S-allyl-L-cysteine, then an intermediate B containing a double bond is prepared by Schiff base reaction of the intermediate A and 5-methoxy-piperonal; then, the intermediate B is copolymerized with methacrylated chitosan and polyethylene glycol diacrylate under light initiation to form a crosslinked network structure; finally, active ingredients such as quercetin-3-O-glucuronide and luteolin-3'-glucuronide are included, and moisturizing agents, preservatives and other auxiliary materials are added to prepare the gel. The gel has a slow-release function, can effectively inhibit glycolysis, reduce lactic acid generation, scavenge free radicals, regulate the inflammatory and fibrotic microenvironment, has good biocompatibility and oxidation response drug release characteristics, and is suitable for the prevention and treatment of scars.

The invention relates to the technical field of biological medicines, in particular to application of a small-molecule inhibitor MYF-03-69 to preparation of a medicine for treating and / or preventing keloid. The MYF-03-69 disclosed by the invention can be used for remarkably promoting fibroblast apoptosis of keloid tissues and inhibiting cell proliferation, and the volume of the keloid tissues can be remarkably reduced by locally injecting the MYF-03-69 into animals in vivo, so that the MYF-03-69 is expected to become an effective drug choice for treating the keloid.

The invention discloses an application of a TEAD inhibitor in preparation of a medicine for treating skin fibrosis, and experiments prove that a TEAD palmitoylation inhibitor MGH-CP1 shows remarkable anti-fibrosis activity in vitro and in vivo, and can effectively inhibit fibroblast activation and ECM deposition induced by TGF-beta or hypoxia. And the pharmaceutical composition has a good curative effect and safety in a bleomycin-induced mouse skin fibrosis model. According to the application of the TEAD inhibitor, a new treatment target and a new treatment strategy are provided for various chronic fibrosis diseases related to skin fibrosis, and the TEAD inhibitor is expected to be clinically applied to improve the treatment effect of the chronic fibrosis diseases represented by systemic sclerosis and keloid, increase the survival rate of patients and prolong the lifetime of the patients.

The invention relates to the technical field of biomedicine and physical therapy, and particularly discloses application of a low-intensity intermediate-frequency alternating sine wave electric field in preparation of a product for inhibiting scar fibroblast proliferation and an electric field therapy device. The electric field is a sinusoidal waveform electric field with the frequency of 100-300 kHz and the intensity of 0.5-3 V / cm, and the preferable parameters are 1.5 V / cm and 150 kHz. The electric field can be applied to a scar or a potential scar formation area through the flexible patch type electrode, proliferation of scar fibroblasts can be remarkably inhibited, apoptosis is promoted, and keloids are prevented and treated. The treatment method provided by the invention is non-invasive, controllable and safe, is suitable for prevention and treatment of scars after operation, burn or trauma, can be combined with the existing treatment means for use, and can be applied to a wearable electric field management system in a family or an outpatient service.

The present invention provides a MPO inhibitor, a method of preparing the same and a new use in the manufacture of a medicament for preventing or treating hypertrophic scars and keloids.

A suspension formulation of clobetasol propionate nanoparticles is described. This suspension can be used therapeutically to treat burns of the skin and eyes, to promote wound healing, to prevent or reduce hypertrophic scarring / keloids, and to treat allergic rhinitis / sinusitis, asthma, inner ear disorders (including hearing loss, tinnitus, or dizziness), tenosynovitis, tendinitis, enthesitis, or arthritis.